North America Drugs for Vulvovaginal Candidiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2023

Publisher Name :
Date: 18-May-2018
No. of pages: 101

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Scope of the Report:

This report focuses on the Drugs for Vulvovaginal Candidiasis in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufacturers, countries, type and application.

Market Segment by Manufacturers, this report covers

- Bayer

- Perrigo

- J & J

- Pfizer

- Bristol-Myers Squibb

- Effik

- Teva

- Sanofi

- Cisen Pharmaceutical

- Kingyork Group

Market Segment by Countries, covering

- Miconazole

- Clotrimazole

- Fluconazole

- Econazole

- Other

Market Segment by Type, covers

- Hospital & Clinic

- Pharmacy

Market Segment by Applications, can be divided into

- Hospital & Clinic

- Pharmacy

There are 15 Chapters to deeply display the North America Drugs for Vulvovaginal Candidiasis market.

Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;

Chapter 2, to analyze the manufacturers of Drugs for Vulvovaginal Candidiasis, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;

Chapter 4, to show the North America market by countries, covering United States, Canada and Mexico, with sales, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each country, from 2013 to 2018;

Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type, application, from 2013 to 2018;

Chapter 7, 8 and 9, to analyze the segment market in United States, Canada and Mexico, by manufacturers, type and application, with sales, price, revenue and market share by manufacturers, types and applications;

Chapter 10, Drugs for Vulvovaginal Candidiasis market forecast, by countries, type and application, with sales, price and revenue, from 2018 to 2023;

Chapter 11, to analyze the manufacturing cost, key raw materials and manufacturing process etc.

Chapter 12, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);

Chapter 13, to describe sales channel, distributors, traders, dealers etc.

Chapter 14 and 15, to describe Drugs for Vulvovaginal Candidiasis Research Findings and Conclusion, Appendix, methodology and data source

North America Drugs for Vulvovaginal Candidiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2023

Table of Contents

1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Introduction
1.2 Market Analysis by Type
1.2.1 Miconazole
1.2.2 Clotrimazole
1.2.3 Fluconazole
1.2.4 Econazole
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 Hospital & Clinic
1.3.2 Pharmacy
1.4 Market Analysis by Countries
1.4.1 United States Status and Prospect (2013-2023)
1.4.2 Mexico Status and Prospect (2013-2023)
1.4.3 Canada Status and Prospect (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Perrigo
2.2.1 Business Overview
2.2.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 J & J
2.3.1 Business Overview
2.3.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Effik
2.6.1 Business Overview
2.6.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Teva
2.7.1 Business Overview
2.7.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sanofi
2.8.1 Business Overview
2.8.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Cisen Pharmaceutical
2.9.1 Business Overview
2.9.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Kingyork Group
2.10.1 Business Overview
2.10.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 North America Drugs for Vulvovaginal Candidiasis Market Competition, by Manufacturer
3.1 North America Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
3.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
3.1.2 North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer (2016-2017)
3.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
3.2.1 North America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
3.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer (2016-2017)
3.3 North America Drugs for Vulvovaginal Candidiasis Price by Manufacturers (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share (2016-2017)
3.4.2 Top 5 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share (2016-2017)
3.5 Market Competition Trend
4 North America Drugs for Vulvovaginal Candidiasis Market Analysis by Countries
4.1 North America Drugs for Vulvovaginal Candidiasis Sales and Market Share by Countries (2013-2018)
4.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
4.1.2 North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
4.2 North America Drugs for Vulvovaginal Candidiasis Revenue (Value) and Market Share by Countries (2013-2018)
4.2.1 North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
4.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
5 North America Market Segmentation Drugs for Vulvovaginal Candidiasis by Type
5.1 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
5.1.1 North America Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
5.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2013-2018)
5.2 Type 1 Sales Growth Rate and Price
5.2 Miconazole Sales Growth and Price
5.2.1 North America Miconazole Sales Growth (2013-2018)
5.2.2 North America Miconazole Price (2013-2018)
5.3 Clotrimazole Sales Growth and Price
5.3.1 North America Clotrimazole Sales Growth (2013-2018)
5.3.2 North America Clotrimazole Price (2013-2018)
5.4 Fluconazole Sales Growth and Price
5.4.1 North America Fluconazole Sales Growth (2013-2018)
5.5 Econazole Sales Growth and Price
5.5.1 North America Econazole Sales Growth (2013-2018)
5.5.2 North America Econazole Price (2013-2018)
5.6 Other Sales Growth and Price
5.6.1 North America Other Sales Growth (2013-2018)
5.6.2 North America Other Price (2013-2018)
6 North America Market Segmentation Drugs for Vulvovaginal Candidiasis by Application
6.1 North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
6.2 Hospital & Clinic Sales Growth (2013-2018)
6.3 Pharmacy Sales Growth (2013-2018)
7 United States Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
7.1 United States Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
7.2 United States Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type
7.2.1 United States Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
7.2.2 United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
7.3 United States Drugs for Vulvovaginal Candidiasis Sales and Market Share by Application (2013-2018)
7.3.1 United States Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
7.3.2 United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
7.4 United States Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
7.4.1 United States Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
7.4.2 United States Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
7.5 United States Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
8 Canada Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
8.1 Canada Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
8.2 Canada Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
8.2.1 Canada Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
8.2.2 Canada Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
8.3 Canada Drugs for Vulvovaginal Candidiasis Sales and Market Share by Application (2013-2018)
8.3.1 Canada Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
8.3.2 Canada Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
8.4 Canada Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
8.4.1 Canada Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
8.4.2 Canada Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
8.5 Canada Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
9 Mexico Drugs for Vulvovaginal Candidiasis Sales, Revenue, by Type, Application and Manufacturers
9.1 Mexico Drugs for Vulvovaginal Candidiasis Revenue, Sales and Growth Rate (2013-2018)
9.2 Mexico Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
9.2.1 Mexico Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
9.2.2 Mexico Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
9.3 Mexico Drugs for Vulvovaginal Candidiasis Sales and Market Share by Application (2013-2018)
9.3.1 Mexico Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
9.3.2 Mexico Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
9.4 Mexico Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Manufacturer (2016-2017)
9.4.1 Mexico Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
9.4.2 Mexico Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
9.5 Mexico Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
10 Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
10.1 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2018-2023)
10.2 Drugs for Vulvovaginal Candidiasis Market Forecast by Countries (2018-2023)
10.2.1 North America Drugs for Vulvovaginal Candidiasis Sales Forecast by Countries (2018-2023)
10.2.2 United States Drugs for Vulvovaginal Candidiasis Forecast (2018-2023)
10.2.3 Canada Drugs for Vulvovaginal Candidiasis Forecast (2018-2023)
10.2.4 Mexico Drugs for Vulvovaginal Candidiasis Forecast (2018-2023)
10.3 Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2018-2023)
10.3.1 North America Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2018-2023)
10.3.2 North America Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2018-2023)
10.4 Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2018-2023)
10.4.1 North America Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2018-2023)
10.4.2 North America Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2018-2023)
11 Drugs for Vulvovaginal Candidiasis Manufacturing Cost Analysis
11.1 Drugs for Vulvovaginal Candidiasis Key Raw Materials Analysis
11.1.1 Key Raw Materials
11.1.2 Price Trend of Key Raw Materials
11.1.3 Key Suppliers of Raw Materials
11.1.4 Market Concentration Rate of Raw Materials
11.2 Proportion of Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
12 Industrial Chain, Sourcing Strategy and Downstream Buyers
12.1 Drugs for Vulvovaginal Candidiasis Industrial Chain Analysis
12.2 Upstream Raw Materials Sourcing
12.3 Raw Materials Sources of Drugs for Vulvovaginal Candidiasis Major Manufacturers in 2017
12.4 Downstream Buyers
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures

Figure Drugs for Vulvovaginal Candidiasis Picture
Table Product Specifications of Drugs for Vulvovaginal Candidiasis
Figure North America Sales Market Share of Drugs for Vulvovaginal Candidiasis by Types in 2017
Table Types of Drugs for Vulvovaginal Candidiasis
Figure Miconazole Picture
Figure Clotrimazole Picture
Figure Fluconazole Picture
Figure Econazole Picture
Figure Other Picture
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Applications in 2017
Table Applications of Drugs for Vulvovaginal Candidiasis
Figure Hospital & Clinic Picture
Figure Pharmacy Picture
Figure United States Drugs for Vulvovaginal Candidiasis Revenue (Million USD) and Growth Rate (2013-2023)
Figure Mexico Drugs for Vulvovaginal Candidiasis Revenue (Million USD) and Growth Rate (2013-2023)
Figure Canada Drugs for Vulvovaginal Candidiasis Revenue (Million USD) and Growth Rate (2013-2023)
Table Bayer Basic Information, Manufacturing Base and Competitors
Table Bayer Drugs for Vulvovaginal Candidiasis Type and Applications
Table Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Perrigo Basic Information, Manufacturing Base and Competitors
Table Perrigo Drugs for Vulvovaginal Candidiasis Type and Applications
Table Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table J & J Basic Information, Manufacturing Base and Competitors
Table J & J Drugs for Vulvovaginal Candidiasis Type and Applications
Table J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Drugs for Vulvovaginal Candidiasis Type and Applications
Table Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Type and Applications
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Effik Basic Information, Manufacturing Base and Competitors
Table Effik Drugs for Vulvovaginal Candidiasis Type and Applications
Table Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Teva Basic Information, Manufacturing Base and Competitors
Table Teva Drugs for Vulvovaginal Candidiasis Type and Applications
Table Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi Drugs for Vulvovaginal Candidiasis Type and Applications
Table Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Cisen Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Type and Applications
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Kingyork Group Basic Information, Manufacturing Base and Competitors
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Type and Applications
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table North America Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Table North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer (2016-2017)
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer (2016-2017)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table North America Drugs for Vulvovaginal Candidiasis Price by Manufacturers (2016-2017)
Figure Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2016
Figure Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2017
Figure Top 5 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2016
Figure Top 5 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2017
Table North America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure North America 2013 Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries
Figure North America 2017 Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
Figure North America 2013 Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries
Figure North America 2017 Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries
Table North America Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Figure North America Miconazole Sales Growth (2013-2018)
Figure North America Miconazole Price (2013-2018)
Figure North America Clotrimazole Sales Growth (2013-2018)
Figure North America Clotrimazole Price (2013-2018)
Figure North America Fluconazole Sales Growth (2013-2018)
Figure North America Fluconazole Price (2013-2018)
Figure North America Econazole Sales Growth (2013-2018)
Figure North America Econazole Price (2013-2018)
Figure North America Other Sales Growth (2013-2018)
Figure North America Other Price (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Figure North America Hospital & Clinic Sales Growth (2013-2018)
Figure North America Pharmacy Sales Growth (2013-2018)
Figure United States Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table United States Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
Table United States Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
Table United States Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table United States Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure United States Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure United States Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table United States Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
Figure Canada Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table Canada Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table Canada Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
Table Canada Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table Canada Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
Table Canada Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Canada Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Canada Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Canada Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Canada Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Canada Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table Canada Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
Figure Mexico Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table Mexico Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table Mexico Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
Table Mexico Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table Mexico Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
Table Mexico Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Mexico Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Mexico Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Mexico Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Mexico Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Mexico Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table Mexico Drugs for Vulvovaginal Candidiasis Export and Import (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2018-2023)
Table North America Drugs for Vulvovaginal Candidiasis Sales Forecast by Countries (2018-2023)
Table North America Drugs for Vulvovaginal Candidiasis Market Share Forecast by Countries (2018-2023)
Figure United States Drugs for Vulvovaginal Candidiasis Sales Forecast (2018-2023)
Figure Canada Drugs for Vulvovaginal Candidiasis Sales Forecast (2018-2023)
Figure Mexico Drugs for Vulvovaginal Candidiasis Sales Forecast (2018-2023)
Table North America Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2018-2023)
Table North America Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2018-2023)
Table North America Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2018-2023)
Table North America Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2018-2023)
Table Sales Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Drugs for Vulvovaginal Candidiasis
Figure Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
Figure Drugs for Vulvovaginal Candidiasis Industrial Chain Analysis
Table Raw Materials Sources of Drugs for Vulvovaginal Candidiasis Major Manufacturers in 2017
Table Major Buyers of Drugs for Vulvovaginal Candidiasis
Table Distributors/Traders/ Dealers List
  • 2018-2023 India Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 16-Aug-2018        Price: US 3360 Onwards        Pages: 84
    In 2017, the Bacterial Vaginosis Drug market size was xx million USD in India, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In India market, the top players include - Pfizer - Teva - Perrigo - Mylan - Lupin Pharmaceuticals - Prasco - West-Ward - Edenvridge Split by product types/category, covering - Clindamycin - Metronidazole - Tinidazole - Other......
  • Global and India Postmenopausal Vaginal Atrophy Treatment Market Research by Company, Type & Application 2013-2025
    Published: 16-Aug-2018        Price: US 2000 Onwards        Pages: 105
    Summary Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase. Market Segment as follows: By Type - Creams - Tablets - Patches......
  • 2018-2023 Philippines Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 16-Aug-2018        Price: US 3360 Onwards        Pages: 84
    In 2017, the Bacterial Vaginosis Drug market size was xx million USD in Philippines, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In Philippines market, the top players include - Pfizer - Teva - Perrigo - Mylan - Lupin Pharmaceuticals - Prasco - West-Ward - Edenvridge Split by product types/category, covering - Clindamycin - Metronidazole - Tinidazole......
  • 2018-2023 UK Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 16-Aug-2018        Price: US 3360 Onwards        Pages: 84
    In 2017, the Bacterial Vaginosis Drug market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In UK market, the top players include - Pfizer - Teva - Perrigo - Mylan - Lupin Pharmaceuticals - Prasco - West-Ward - Edenvridge Split by product types/category, covering - Clindamycin - Metronidazole - Tinidazole - Other ......
  • 2018-2023 United States Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 16-Aug-2018        Price: US 3360 Onwards        Pages: 84
    In 2017, the Bacterial Vaginosis Drug market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In United States market, the top players include - Pfizer - Teva - Perrigo - Mylan - Lupin Pharmaceuticals - Prasco - West-Ward - Edenvridge Split by product types/category, covering - Clindamycin - Metronidazole - Tinidazole......
  • Vulvovaginal Candidiasis - Market Insights, Epidemiology and Market Forecast - 2027
    Published: 03-Aug-2018        Price: US 6250 Onwards        Pages: 120
    DelveInsight's ‘Vulvovaginal Candidiasis - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Vulvovaginal Candidiasis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size......
  • Global Drugs for Vulvovaginal Candidiasis Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 02-Aug-2018        Price: US 3480 Onwards        Pages: 131
    The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Drugs for Vulvovaginal Candidiasis Market 2018, Forecast to 2023
    Published: 02-Aug-2018        Price: US 4880 Onwards        Pages: 136
    The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after ......
  • 2018-2023 Global Drugs for Vulvovaginal Candidiasis Consumption Market Report
    Published: 02-Aug-2018        Price: US 4660 Onwards        Pages: 131
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Drugs for Vulvovaginal Candidiasis market for 2018-2023. The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs